Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation
Microfluidic polymeric blood vessel captures the adverse effects of SARS-CoV-2 on vasculature and enables identification of a therapeutic peptide that abolished virus induced cytokine storm orchestrated by the immune cells.
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | englanti |
| Julkaistu: |
2022
|
| Linkit: | https://doi.org/10.1039/d1lc00817j |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|